Thus, to initially characterize the mechanisms of CAPS action in inhibiting the proliferation, cell cycle progression and motility of MM cells, we tested the level of AKT and ERK1/2 activation by immunoblot in NCI-H2052 (Figure 7a), MSTO-211H (Figure 7b) and NCI-H28 (Figure 7c) cells with and without CAPS treatment. The gene discussed is AKT1; the disease is Miyoshi myopathy.